The global neuroendocrine carcinoma treatment market is projected to grow significantly, with an estimated value of USD 1,976 million in 2024 and a compound annual growth rate (CAGR) of 8.1% from 2024 to 2034. This growth trajectory is expected to propel the market size to approximately USD 4,305.7 million by 2034, reflecting the increasing incidence of neuroendocrine cancers and advancements in treatment options.
A key factor contributing to the market’s expansion is the improved detection rates of neuroendocrine cancers, facilitated by a growing number of biological markers and well-established diagnostic methods. Governments in both developed and developing nations are actively promoting awareness programs aimed at early cancer diagnosis, which can lead to significantly better treatment outcomes.
Innovative research is underway to develop intelligent chemotherapy that selectively targets tumor cells while sparing healthy cells. This strategic approach aims to reduce adverse effects and enhance therapeutic efficacy. Current treatment protocols for advanced neuroendocrine tumors include systemic therapies such as chemotherapy and targeted therapy. Chemotherapy agents, including etoposide and cisplatin, are utilized to eliminate rapidly dividing cancer cells. Furthermore, treatments like somatostatin analogs and tyrosine kinase inhibitors specifically target pathways responsible for tumor growth and spread.
Research institutions, such as the Dana-Farber Brigham Cancer Center’s Neuroendocrine and Carcinoid Tumors Program, are conducting groundbreaking studies to identify the molecular pathways contributing to the development of neuroendocrine tumors. These efforts aim to uncover new targets for therapy and accelerate the development of more effective treatment approaches.
Emerging molecular and clinical findings are challenging established treatment paradigms for neuroendocrine carcinomas. Investigations are underway into therapies that do not rely on tumors as sources of resistance. Key areas of research focus on specific genetic alterations, including RET and NTRK gene fusions, as well as BRAF or KRAS inhibitors, with studies exploring characteristics such as microsatellite instability and high tumor mutational burden.
As the neuroendocrine carcinoma treatment landscape evolves, the combination of increased awareness, advanced diagnostic methods, and targeted therapies promises to enhance patient outcomes and drive market growth in the coming years.
“Cure for neuroendocrine carcinomas and the development of new cancer vaccines and drugs with targeted therapies are expected to see increased growth in the near future. The combination of increased clinical studies and the launch of new products will continue to drive the industry forward.” – Says an analyst at FMI.
Key Takeaways from the Neuroendocrine Carcinoma Treatment Market:
- In 2023, gastric neuroendocrine tumors accounted for 46.8% share of global revenue.
- In the United States, the market is expected to expand at a CAGR of 8.3% through 2034.
- Market growth in France is expected to take place at a CAGR of 7.5% during the forecast period.
- A CAGR of 9% is expected to be observed between 2024 and 2034 for the market in India.
- Based on treatment type, somatostatin analogs held 61.2% of the market in 2023.
Expanding Market Need: Access Our Full Report for In-Depth Analysis and Trends!
Competitive Landscape:
Market players work closely with regulatory agencies to ensure safety and efficacy standards are met and to expedite approval processes. Neuroendocrine carcinoma treatments are often researched and developed at great expense by businesses. For clinical trials to be successful, preclinical research is also fundamental to the identification and development of potential therapeutic targets. New medicines are being evaluated in clinical trials to determine their efficacy and safety. Patients and healthcare professionals often participate in clinical studies to assess the efficacy of their treatments.
Recent Development:
- In September 2023, Novartis targeted Lutathera for first-line use in neuroendocrine tumors after a successful trial. The United States Food and Drug Administration (FDA) approved Lutathera in 2018 for the treatment of GEP-NETs with somatostatin receptor positivity. Novartis pointed to the positive phase 3 NETTER-2 trial readout to highlight Lutathera’s clinically meaningful progression-free survival benefit.
- In April 2024, Pfizer and Genmab announced the United States FDA had approved the supplemental Biologics License Application (sBLA) granting full approval for TIVDAK (tisotumab vedotin-tftv) as a therapy for patients with recurrent or metastatic cervical cancer.
Company Profile:
- Pfizer Inc.
- Novartis AG
- Chiasma Inc.
- Hutchison China MediTech Ltd
- Abbvie Inc.
- Valeant Pharmaceuticals International Inc.
- Jubilant Life Sciences Ltd.
- Teva Pharmaceutical Industries Ltd
- F. Hoffmann-La Roche Ltd
- Advanced Accelerator Applications
- Mateon Therapeutics, Inc.
Key Segments of Market Report:
By Disease Indication Type:
Based on disease indication type, the industry is classified into gastric neuroendocrine tumors, lung neuroendocrine tumors, pancreatic neuroendocrine tumors, and appendicular neuroendocrine tumors.
By Treatment Type:
Based on the treatment type, the industry is categorized into somatostatin analogs, targeted therapy (tyrosine kinase inhibitors, mTOR inhibitors), and chemotherapy (antimetabolites, alkylating agents, natural products).
By End User:
In terms of end users, the industry is classified into hospitals, clinics, oncology centers, and ambulatory surgery centers.
By Region:
Key countries of North America, Latin America, East Asia, South Asia, Western Europe, Eastern Europe, and the Middle East and Africa are covered in the regional analysis.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube